<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975323</url>
  </required_header>
  <id_info>
    <org_study_id>20-2605/R&amp;D/HEC/12</org_study_id>
    <nct_id>NCT02975323</nct_id>
  </id_info>
  <brief_title>Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension</brief_title>
  <acronym>DPH</acronym>
  <official_title>Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension (DPH Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Portal hypertension is the result of an increased hepatic vascular resistance and portal&#xD;
      inflow. The best established method to assess portal pressures is the determination of wedged&#xD;
      hepatic venous pressure gradient (HVPG). Ultrasound Doppler technique is non-invasive in the&#xD;
      assessment of portal hypertension as compared with invasive technique of measurement of the&#xD;
      hepatic venous pressure gradient (HVPG). Hemodynamic measurements (BP and pulse recording)&#xD;
      will be done and then patient will be given tablet Carvedilol 12.5 mg in a single dose and&#xD;
      wait till the time that 20% reduction in heart rate from the baseline occurs. Haemodynamic&#xD;
      measurements will be repeated to assess the acute response to beta-adrenoreceptor blocker&#xD;
      agent. The change in the HWF will be recorded post beta-adrenoreceptor blocker&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ultrasound Doppler technique is non-invasive in the assessment of portal hypertension as&#xD;
      compared with invasive technique of measurement of the hepatic venous pressure gradient&#xD;
      (HVPG). The Doppler waveform of the hepatic vein in healthy subjects is normally triphasic&#xD;
      (two negative waves and one positive wave) because of central venous pressure variations due&#xD;
      to the cardiac cycle. The normal triphasic hepatic vein waveform is transformed into a&#xD;
      biphasic or monophasic waveform in patients with cirrhosis. A monophasic waveform has been&#xD;
      shown to correlate with a high Child-Pugh score and a poor survival rate.&#xD;
&#xD;
      Therefore, Hepatic vein waveform (HVWF) evaluation with Doppler US may be used as a&#xD;
      supplemental tool to assess the severity of Portal Hypertension and therapeutic response to&#xD;
      portal pressure lowering drugs in primary prophylaxis of variceal bleed in patients with&#xD;
      large oesophageal varices. There's one study which has looked into the same topic but it has&#xD;
      been conducted on alcoholic cirrhotics.&#xD;
&#xD;
      Doppler ultrasound is a non-invasive tool in the measurement of portal pressure in portal&#xD;
      hypertensive patients. Hemodynamic measurements (BP and pulse recording) will be done and&#xD;
      then patient will be given tablet Carvedilol 12.5 mg in a single dose and wait till the time&#xD;
      that 20% reduction in heart rate from the baseline occurs. Haemodynamic measurements will be&#xD;
      repeated to assess the acute response to beta-adrenoreceptor blocker agent. The change in the&#xD;
      HWF will be recorded post beta-adrenoreceptor blocker administration. This study will be a&#xD;
      validation and interventional study. It is an open labeled study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Correlation of HWF as detected on doppler ultrasound (tri-, bi,- monophasic pattern) and HVPG (mm Hg) as assessed at hepatic vein catherization in the portal hypertensive patient .</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To administer Carvedilol 12.5 mg orally and measure Wedge pressure gradient in hepatic veins followed by change in hepatic vein wave form</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.</description>
    <arm_group_label>Single</arm_group_label>
    <other_name>carveda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with cirrhosis and large varices (â‰¥ 5mm) on screening endoscopy&#xD;
&#xD;
          -  Not known esophageal or gastric variceal bleed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Small esophageal varices (&lt;5 mm in size) on screening endoscopy&#xD;
&#xD;
          -  Hemodynamically unstable i.e. Blood pressure of &lt;90mmHg and tachycardia of &gt;100bpm.&#xD;
&#xD;
          -  Contraindication to Beta-blockers (Asthma, bradycardia, heart failure, allergy)&#xD;
&#xD;
          -  history of Esophageal or gastric variceal bleed in the past&#xD;
&#xD;
          -  Hepatocellular carcinoma or other metastatic malignancy.&#xD;
&#xD;
          -  Portal vein thrombosis (PVT) or Inferior venacaval (IVC) thrombosis&#xD;
&#xD;
          -  Congestive cardiac failure (CCF)&#xD;
&#xD;
          -  Renal failure or Hepatorenal syndrome (Creatine of &gt;1.5 mg/dl)&#xD;
&#xD;
          -  Previous allergy to IV contrast agent.&#xD;
&#xD;
          -  Lactating or Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Syed Hasnain A Shah, M.D.</last_name>
    <phone>00922134864676</phone>
    <email>hasnain.alishah@aku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aga Khan University,</name>
      <address>
        <city>Karachi</city>
        <state>Sind</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasneem Khan, MBA</last_name>
      <phone>00922134864670</phone>
      <email>tasneem.khan@aku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aga Khan University</investigator_affiliation>
    <investigator_full_name>Dr. Syed Hasnain Ali Shah</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatic venous pressure gradient</keyword>
  <keyword>liver disease</keyword>
  <keyword>US Doppler waveform</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

